• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

慢性阻塞性肺疾病的三联疗法（吸入性糖皮质激素/长效β2受体激动剂/长效抗胆碱能药物）：突破常规思维。

Triple therapy (ICS/LABA/LAMA) in COPD: thinking out of the box.

作者信息

Vanfleteren Lowie E G W, Ullman Anders, Nordenson Anita, Andersson Anders, Andelid Kristina, Fabbri Leonardo M

机构信息

COPD center, Institute of Medicine, Sahlgrenska University Hospital, University of Gothenburg, Gothenburg, Sweden.

出版信息

ERJ Open Res. 2019 Feb 11;5(1). doi: 10.1183/23120541.00185-2018. eCollection 2019 Feb.

DOI:10.1183/23120541.00185-2018
PMID:30775372
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6368994/
Abstract

http://ow.ly/CbOe30njXV2.

摘要

http://ow.ly/CbOe30njXV2.（此为网址，无法准确完整翻译其含义，保留原文形式）

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4dc4/6368994/6d9c5437648a/00185-2018.01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4dc4/6368994/6d9c5437648a/00185-2018.01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4dc4/6368994/6d9c5437648a/00185-2018.01.jpg

相似文献

1
Triple therapy (ICS/LABA/LAMA) in COPD: thinking out of the box.慢性阻塞性肺疾病的三联疗法（吸入性糖皮质激素/长效β2受体激动剂/长效抗胆碱能药物）：突破常规思维。
ERJ Open Res. 2019 Feb 11;5(1). doi: 10.1183/23120541.00185-2018. eCollection 2019 Feb.
2
The effects of single inhaler triple therapy vs single inhaler dual therapy or separate triple therapy for the management of chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized controlled trials.单吸入器三联疗法与单吸入器双联疗法或单独三联疗法治疗慢性阻塞性肺疾病的效果：系统评价和随机对照试验的荟萃分析。
Int J Chron Obstruct Pulmon Dis. 2019 Jul 11;14:1539-1548. doi: 10.2147/COPD.S200846. eCollection 2019.
3
Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal.慢性阻塞性肺疾病中的三联疗法（吸入性糖皮质激素/长效β2受体激动剂/长效抗胆碱能药物）：是时候重新评估了。
Int J Chron Obstruct Pulmon Dis. 2018 Dec 12;13:3971-3981. doi: 10.2147/COPD.S185975. eCollection 2018.
4
Adding a LAMA to ICS/LABA Therapy: A Meta-analysis of Triple Combination Therapy in COPD.在 ICS/LABA 治疗中添加 LAMA：COPD 三联疗法的荟萃分析。
Chest. 2019 Apr;155(4):758-770. doi: 10.1016/j.chest.2018.12.016. Epub 2019 Jan 17.
5
Comparative Effectiveness and Safety of LABA-LAMA vs LABA-ICS Treatment of COPD in Real-World Clinical Practice.在真实临床实践中，LABA-LAMA 与 LABA-ICS 治疗 COPD 的疗效和安全性比较。
Chest. 2019 Jun;155(6):1158-1165. doi: 10.1016/j.chest.2019.03.005. Epub 2019 Mar 26.
6
The IMPACT of triple dual single-inhaler therapy on exacerbations of COPD.三联、双联和单吸入器疗法对慢性阻塞性肺疾病急性加重的影响
Breathe (Sheff). 2018 Dec;14(4):333-335. doi: 10.1183/20734735.026418.
7
Role of Long-Acting Muscarinic Antagonist/Long-Acting β-Agonist Therapy in Chronic Obstructive Pulmonary Disease.长效毒蕈碱拮抗剂/长效β受体激动剂疗法在慢性阻塞性肺疾病中的作用
Ann Pharmacother. 2017 Aug;51(8):696-705. doi: 10.1177/1060028017705149. Epub 2017 Apr 14.
8
Current appraisal of single inhaler triple therapy in COPD.慢性阻塞性肺疾病（COPD）单一吸入器三联疗法的当前评估
Int J Chron Obstruct Pulmon Dis. 2018 Sep 28;13:3003-3009. doi: 10.2147/COPD.S177333. eCollection 2018.
9
Comparative Effectiveness of Long-Acting Beta -Agonist Combined with a Long-Acting Muscarinic Antagonist or Inhaled Corticosteroid in Chronic Obstructive Pulmonary Disease.长效β受体激动剂联合长效毒蕈碱拮抗剂或吸入性糖皮质激素治疗慢性阻塞性肺疾病的比较疗效
Pharmacotherapy. 2017 Apr;37(4):447-455. doi: 10.1002/phar.1913.
10
Clinical characteristics and medication patterns in patients with COPD prior to initiation of triple therapy with ICS/LAMA/LABA: A retrospective study.在开始三联疗法（ICS/LAMA/LABA）治疗之前，COPD 患者的临床特征和用药模式：一项回顾性研究。
Respir Med. 2018 Sep;142:73-80. doi: 10.1016/j.rmed.2018.07.009. Epub 2018 Jul 17.

引用本文的文献

1
An Italian Delphi Consensus on the Triple inhalation Therapy in Chronic Obstructive Pulmonary Disease.意大利慢性阻塞性肺疾病三联吸入疗法德尔菲共识
Multidiscip Respir Med. 2024 Sep 18;19(1):949. doi: 10.5826/mrm.2024.949.
2
Phenotyping asthma with airflow obstruction in middle-aged and older adults: a CADSET clinical research collaboration.用中年和老年人的气流阻塞表型哮喘：CADSET 临床研究合作。
BMJ Open Respir Res. 2023 Aug;10(1). doi: 10.1136/bmjresp-2023-001760.
3
Prompt initiation of triple therapy following hospitalization for a chronic obstructive pulmonary disease exacerbation in the United States: An analysis of the PRIMUS study.

本文引用的文献

1
Preventing clinically important deterioration with single-inhaler triple therapy in COPD.使用单吸入器三联疗法预防慢性阻塞性肺疾病（COPD）的临床显著恶化。
ERJ Open Res. 2018 Oct 3;4(4). doi: 10.1183/23120541.00047-2018. eCollection 2018 Oct.
2
Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial.布地奈德/格隆溴铵/富马酸福莫特罗联合混悬液给药技术三联疗法对比慢性阻塞性肺疾病（KRONOS）中的双联疗法：一项双盲、平行分组、多中心、3 期随机对照临床试验。
Lancet Respir Med. 2018 Oct;6(10):747-758. doi: 10.1016/S2213-2600(18)30327-8. Epub 2018 Sep 16.
3
美国慢性阻塞性肺病加重住院后启动三联疗法的提示：PRIMUS 研究分析。
J Manag Care Spec Pharm. 2022 Dec;28(12):1366-1377. doi: 10.18553/jmcp.2022.28.12.1366.
4
Use of single-inhaler triple therapy in the management of obstructive airway disease: Indian medical experts' review.单吸入器三联疗法在阻塞性气道疾病管理中的应用：印度医学专家综述
ERJ Open Res. 2022 Mar 28;8(1). doi: 10.1183/23120541.00556-2021. eCollection 2022 Jan.
5
Patient-Centered Discussion on End-of-Life Care for Patients with Advanced COPD.以患者为中心的晚期 COPD 患者临终关怀讨论。
Medicina (Kaunas). 2022 Feb 8;58(2):254. doi: 10.3390/medicina58020254.
6
Beyond Dual Bronchodilation - Triple Therapy, When and Why.超越双支气管扩张 - 三联疗法，何时及为何。
Int J Chron Obstruct Pulmon Dis. 2022 Jan 14;17:165-180. doi: 10.2147/COPD.S345263. eCollection 2022.
7
A Real World Study to Assess the Effectiveness of Switching to Once Daily Closed Triple Therapy from Mono/Dual Combination or Open Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease.一项真实世界研究，旨在评估慢性阻塞性肺疾病患者由单药/双联联合或开放三联疗法转换为每日一次三联闭合疗法的疗效。
Int J Chron Obstruct Pulmon Dis. 2021 Jun 3;16:1555-1568. doi: 10.2147/COPD.S308911. eCollection 2021.
8
When to Use Initial Triple Therapy in COPD: Adding a LAMA to ICS/LABA by Clinically Important Deterioration Assessment.COPD 初始三联治疗的时机：根据临床重要恶化评估，在 ICS/LABA 中添加 LAMA。
Int J Chron Obstruct Pulmon Dis. 2020 Dec 22;15:3375-3384. doi: 10.2147/COPD.S279482. eCollection 2020.
9
Single-inhaler triple therapy in patients with chronic obstructive pulmonary disease: a systematic review.单吸入器三联疗法治疗慢性阻塞性肺疾病患者：系统评价。
Respir Res. 2019 Nov 4;20(1):242. doi: 10.1186/s12931-019-1213-9.
Inhaled corticosteroid containing combinations and mortality in COPD.慢性阻塞性肺疾病中含吸入性皮质类固醇的联合用药与死亡率
Eur Respir J. 2018 Dec 13;52(6). doi: 10.1183/13993003.01230-2018. Print 2018 Dec.
4
High or low impact? Triple therapy in chronic obstructive pulmonary disease.高影响还是低影响？慢性阻塞性肺疾病的三联疗法。
Respirology. 2018 Oct;23(10):891-892. doi: 10.1111/resp.13388. Epub 2018 Aug 20.
5
Management of severe COPD exacerbations: focus on beclomethasone dipropionate/formoterol/glycopyrronium bromide.重度慢性阻塞性肺疾病急性加重的管理：聚焦于丙酸倍氯米松/福莫特罗/格隆溴铵
Int J Chron Obstruct Pulmon Dis. 2018 Jul 30;13:2319-2333. doi: 10.2147/COPD.S147484. eCollection 2018.
6
Blood eosinophils in COPD and the future risk of pneumonia.慢性阻塞性肺疾病中的血液嗜酸性粒细胞与未来肺炎风险
Eur Respir J. 2018 Jul 27;52(1). doi: 10.1183/13993003.00981-2018. Print 2018 Jul.
7
Single inhaler triple therapy with extrafine beclomethasone, formoterol, and glycopyrronium for the treatment of chronic obstructive pulmonary disease.布地奈德福莫特罗格隆溴铵干粉吸入剂治疗慢性阻塞性肺疾病
Expert Opin Pharmacother. 2018 Aug;19(11):1279-1287. doi: 10.1080/14656566.2018.1498841. Epub 2018 Aug 13.
8
Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD.COPD 患者每日一次单吸入器三联与双联治疗。
N Engl J Med. 2018 May 3;378(18):1671-1680. doi: 10.1056/NEJMoa1713901. Epub 2018 Apr 18.
9
Natural History of Chronic Obstructive Pulmonary Disease Exacerbations in a General Practice-based Population with Chronic Obstructive Pulmonary Disease.慢性阻塞性肺疾病患者在一般实践人群中的慢性阻塞性肺疾病加重的自然史。
Am J Respir Crit Care Med. 2018 Aug 15;198(4):464-471. doi: 10.1164/rccm.201710-2029OC.
10
Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial.特布他林、布地奈德/福莫特罗和茚达特罗/格隆溴铵治疗慢性阻塞性肺疾病（TRIBUTE）的随机对照双盲平行分组研究
Lancet. 2018 Mar 17;391(10125):1076-1084. doi: 10.1016/S0140-6736(18)30206-X. Epub 2018 Feb 9.